Linaclotide: A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome

Brian E. Lacy, John M. Levenick, Michael D. Crowell

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12% of the US population meet the diagnostic criteria for IBS, and 15% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.

Original languageEnglish (US)
Pages (from-to)653-660
Number of pages8
JournalGastroenterology and Hepatology
Volume8
Issue number10
StatePublished - Oct 1 2012

Keywords

  • Abdominal pain
  • Bloating
  • Constipation
  • Guanylyl cyclase
  • Irritable bowel syndrome
  • Linaclotide

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Linaclotide: A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome'. Together they form a unique fingerprint.

Cite this